HUP0402376A2 - Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények - Google Patents
Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítményekInfo
- Publication number
- HUP0402376A2 HUP0402376A2 HU0402376A HUP0402376A HUP0402376A2 HU P0402376 A2 HUP0402376 A2 HU P0402376A2 HU 0402376 A HU0402376 A HU 0402376A HU P0402376 A HUP0402376 A HU P0402376A HU P0402376 A2 HUP0402376 A2 HU P0402376A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- alkyl
- imidazole
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- ZBNZAJFNDPPMDT-UHFFFAOYSA-N 1h-imidazole-5-carboxamide Chemical class NC(=O)C1=CNC=N1 ZBNZAJFNDPPMDT-UHFFFAOYSA-N 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- -1 sulfonylaminocarbonyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
A találmány az (I) általános képletű vegyületekre vonatkozik, amelyekképletében R1 és R2 jelentése azonosan vagy különbözően adott esetbenalkilcsoporttal helyettesített fenilcsoport, alkilcsoport, adottesetben helyettesített ciklohexilcsoport, adott esetben helyettesített1-naftil- vagy 2-naftil-csoport, adott esetben fenilgyűrűjénhelyettesített benzilcsoport, adott esetben 5-10 tagú telített vagytelítetlen heterociklusos csoport vagy adott esetben helyettesített 5-10 tagú aromás monociklusos vagy biciklusos heterociklusos csoport; R3jelentése hidrogén-, klór- vagy brómatom, alkil- vagy benzilcsoport; Xjelentése mono- vagy diszubsztituált aminokarbonil-csoport, ahol ahelyettesítők a hozzájuk kapcsolódó nitrogénatommal együtt 5-10 tagútelített vagy telítetlen heterociklusos csoportot képezhetnek, amelyadott esetben helyettesített; vagy X jelentése adott esetbenhelyettesített szulfonilaminokarbonil-csoport, 5-10-tagú aromásmonociklusos vagy biciklusos heterociklilkarbonil-csoport; továbbáezek gyógyászatilag elfogadható sói és észterei. A találmány kiterjeda fenti vegyületeket tartalmazó étvágycsökkentő és tömegcsökkentőhatású készítményekre, valamint ezek alkalmazására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32447301P | 2001-09-24 | 2001-09-24 | |
PCT/US2002/030545 WO2003040107A1 (en) | 2001-09-24 | 2002-09-24 | Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0402376A2 true HUP0402376A2 (hu) | 2005-02-28 |
Family
ID=23263739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0402376A HUP0402376A2 (hu) | 2001-09-24 | 2002-09-24 | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények |
Country Status (25)
Country | Link |
---|---|
US (2) | US6960601B2 (hu) |
EP (1) | EP1432691A1 (hu) |
JP (1) | JP2005508384A (hu) |
KR (1) | KR20040040472A (hu) |
CN (2) | CN1865248A (hu) |
AR (1) | AR036608A1 (hu) |
BR (1) | BR0212986A (hu) |
CA (1) | CA2459745A1 (hu) |
CO (1) | CO5560560A2 (hu) |
EC (1) | ECSP045076A (hu) |
GT (1) | GT200200188A (hu) |
HN (1) | HN2002000266A (hu) |
HR (1) | HRP20040308A2 (hu) |
HU (1) | HUP0402376A2 (hu) |
IL (1) | IL160524A0 (hu) |
MA (1) | MA27684A1 (hu) |
MX (1) | MXPA04002037A (hu) |
NO (1) | NO20041216L (hu) |
NZ (1) | NZ531841A (hu) |
PE (1) | PE20030547A1 (hu) |
PL (1) | PL369326A1 (hu) |
RU (1) | RU2004112770A (hu) |
UY (1) | UY27450A1 (hu) |
WO (1) | WO2003040107A1 (hu) |
ZA (1) | ZA200403035B (hu) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
CA2478183C (en) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Substituted amides |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AU2003299791A1 (en) * | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
RU2339618C2 (ru) | 2003-01-02 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг | Новые обратные агонисты рецептора св1 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
CA2522536A1 (en) * | 2003-04-21 | 2004-11-04 | Daiichi Pharmaceutical Co., Ltd. | Five-membered heterocyclic derivative |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
CA2533898A1 (en) | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
MEP15908A (en) | 2003-10-08 | 2010-06-10 | Bayer Schering Pharma Ag | 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics |
CA2543338A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
MXPA06004642A (es) | 2003-11-05 | 2006-06-27 | Hoffmann La Roche | Derivados de heteroaril como activadores de los receptores activados de proliferadores de peroxisoma (ppar). |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
RU2360909C2 (ru) | 2004-01-28 | 2009-07-10 | Ф.Хоффманн-Ля Рош Аг | Новые спиропентациклические соединения |
US7173044B2 (en) * | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
CA2558214A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
CN1938023A (zh) * | 2004-03-08 | 2007-03-28 | 惠氏公司 | 离子通道调节剂 |
US20080242716A1 (en) * | 2004-03-08 | 2008-10-02 | Robert Zelle | Ion Channel Modulators |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US7799804B2 (en) * | 2004-04-03 | 2010-09-21 | Astrazeneca Ab | Therapeutic agents |
US20080153859A1 (en) | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
WO2005108393A1 (en) | 2004-05-10 | 2005-11-17 | F. Hoffmann-La Roche Ag | Pyrrole or imidazole amides for treating obesity |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
US7524867B2 (en) | 2004-05-28 | 2009-04-28 | Solvay Pharmaceuticals, B.V. | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity |
TW200616969A (en) * | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
WO2006045799A2 (en) | 2004-10-25 | 2006-05-04 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
ES2351348T3 (es) | 2004-11-09 | 2011-02-03 | F. Hoffmann-La Roche Ag | Derivados de la dibenzosuberona. |
WO2006060190A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Imidazole derivatives |
WO2006060199A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Imidazole derivatives for the treatment of sexual dysfunction |
CA2594488C (en) * | 2005-01-10 | 2015-04-28 | University Of Connecticut | Novel heteropyrrole analogs acting on cannabinoid receptors |
JP2008528700A (ja) * | 2005-02-03 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Pparモジュレーターとしての化合物および組成物 |
US20070026079A1 (en) * | 2005-02-14 | 2007-02-01 | Louis Herlands | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels |
US8937184B2 (en) | 2005-02-16 | 2015-01-20 | Abbvie B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
DE102005017316A1 (de) * | 2005-04-14 | 2006-10-19 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
NZ583758A (en) | 2005-05-12 | 2011-02-25 | Abbott Lab | Apoptosis promoters |
CA2613517A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
AT502258B1 (de) * | 2005-07-22 | 2007-09-15 | Univ Wien | Cox-i-inhibitorverbindungen |
CA2618568A1 (en) | 2005-08-18 | 2007-02-22 | F. Hoffmann-La Roche Ag | Thiazolyl piperidine derivatives useful as h3 receptor modulators |
GB0518817D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
GB0518819D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
US7829586B2 (en) * | 2005-09-30 | 2010-11-09 | Banyu Pharmaceutical Co., Ltd. | Aryl-substituted nitrogen-containing heterocyclic compounds |
US7714126B2 (en) | 2005-11-28 | 2010-05-11 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
EP1834948A1 (de) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
CA2649927A1 (en) * | 2006-04-14 | 2007-10-25 | Merck & Co., Inc. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
EP2010179B1 (en) * | 2006-04-14 | 2010-07-07 | Merck Sharp & Dohme Corp. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
US7795265B2 (en) * | 2006-04-14 | 2010-09-14 | Merck Sharp & Dohme Corp. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
AU2008209472A1 (en) | 2007-01-26 | 2008-07-31 | Merck Sharp & Dohme Corp. | Substituted aminopyrimidines as cholecystokinin-1 receptor modulators |
MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
GB2451629A (en) * | 2007-08-06 | 2009-02-11 | Univ Sheffield | 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
HUE043569T2 (hu) * | 2008-06-16 | 2019-08-28 | Univ Tennessee Res Found | Vegyületek rák kezelésére |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
PE20142316A1 (es) * | 2008-12-05 | 2015-02-04 | Abbvie Inc | DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
US8809538B2 (en) | 2009-01-12 | 2014-08-19 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
DK2470552T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
KR20120130777A (ko) | 2010-03-01 | 2012-12-03 | 유니버시티 오브 테네시 리서치 파운데이션 | 암 치료용 화합물 |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
KR101564806B1 (ko) | 2010-05-13 | 2015-10-30 | 암젠 인크 | Pde10 저해제로서 유용한 질소 헤테로시클릭 화합물 |
EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MA34916B1 (fr) | 2011-02-25 | 2014-02-01 | Merck Sharp & Dohme | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP6767878B2 (ja) | 2014-06-06 | 2020-10-14 | リサーチ トライアングル インスティテュート | アペリン受容体(apj)アゴニストおよびそれらの使用 |
RU2766148C1 (ru) | 2015-12-09 | 2022-02-08 | Рисерч Трайэнгл Инститьют | Улучшенные агонисты апелинового рецептора (apj) и их использование |
CA3017547A1 (en) * | 2016-03-15 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | Substituted sulfonyl amides for controlling animal pests |
CN109790151B (zh) * | 2016-10-12 | 2022-03-29 | 三角研究所 | 杂环爱帕琳肽受体(apj)激动剂及其用途 |
TW201822637A (zh) * | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
AU2017360941A1 (en) * | 2016-11-18 | 2019-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP4055010A1 (de) | 2019-11-07 | 2022-09-14 | Bayer Aktiengesellschaft | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE140966C (hu) | ||||
US5091405A (en) | 1987-01-05 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Insecticidal pyrazolines |
DE3808071A1 (de) | 1988-03-11 | 1989-09-21 | Basf Ag | Verfahren zur herstellung von acylierten imidazolen |
US5164406A (en) | 1988-06-02 | 1992-11-17 | Bristol-Myers Squibb Co. | Method for enhancing transdermal penetration and compositions useful therein |
DE4015535A1 (de) | 1990-05-15 | 1991-11-21 | Basf Ag | Verfahren zur herstellung von n-substituierten imidazolen |
DE69322254T2 (de) | 1992-01-13 | 1999-04-29 | Smithkline Beecham Corp | Pyridyl-substituierte imidazole |
US5550147A (en) | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5565577A (en) | 1992-09-23 | 1996-10-15 | Smithkline Beecham Corporation | Process for preparing 1-alkyaryl-2-alkyl-5-formylimidazole |
DE69432193T2 (de) * | 1993-11-30 | 2004-01-15 | Searle & Co | Substituierte Pyrazolyl-benzolsulfonamide und ihre Verwendung als CyclooxygenaseII Inhibitoren |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5519143A (en) | 1994-09-19 | 1996-05-21 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of an imidazole stereoisomer from a mixture of stereoisomers by selective precipitation |
CA2275610A1 (en) | 1996-12-16 | 1998-06-25 | Ontogen Corporation | Modulators of proteins with phosphotyrosine recognition units |
IL136637A0 (en) | 1997-12-22 | 2001-06-14 | Du Pont Pharm Co | Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors |
US6291476B1 (en) * | 1999-05-12 | 2001-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
US6492516B1 (en) | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
PE20011010A1 (es) | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
WO2002064136A2 (en) | 2001-01-26 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
-
2002
- 2002-09-23 GT GT200200188A patent/GT200200188A/es unknown
- 2002-09-23 PE PE2002000931A patent/PE20030547A1/es not_active Application Discontinuation
- 2002-09-23 HN HN2002000266A patent/HN2002000266A/es unknown
- 2002-09-23 UY UY27450A patent/UY27450A1/es unknown
- 2002-09-23 AR ARP020103574A patent/AR036608A1/es unknown
- 2002-09-24 HU HU0402376A patent/HUP0402376A2/hu unknown
- 2002-09-24 IL IL16052402A patent/IL160524A0/xx unknown
- 2002-09-24 JP JP2003542153A patent/JP2005508384A/ja not_active Withdrawn
- 2002-09-24 CA CA002459745A patent/CA2459745A1/en not_active Abandoned
- 2002-09-24 EP EP02780365A patent/EP1432691A1/en not_active Withdrawn
- 2002-09-24 CN CNA2006100915133A patent/CN1865248A/zh active Pending
- 2002-09-24 US US10/255,049 patent/US6960601B2/en not_active Expired - Fee Related
- 2002-09-24 MX MXPA04002037A patent/MXPA04002037A/es unknown
- 2002-09-24 CN CNA028186931A patent/CN1599724A/zh active Pending
- 2002-09-24 RU RU2004112770/04A patent/RU2004112770A/ru not_active Application Discontinuation
- 2002-09-24 KR KR10-2004-7004228A patent/KR20040040472A/ko not_active Application Discontinuation
- 2002-09-24 PL PL02369326A patent/PL369326A1/xx not_active Application Discontinuation
- 2002-09-24 WO PCT/US2002/030545 patent/WO2003040107A1/en not_active Application Discontinuation
- 2002-09-24 BR BR0212986-8A patent/BR0212986A/pt not_active IP Right Cessation
- 2002-09-24 NZ NZ531841A patent/NZ531841A/en unknown
-
2004
- 2004-03-19 CO CO04026619A patent/CO5560560A2/es not_active Application Discontinuation
- 2004-03-23 NO NO20041216A patent/NO20041216L/no not_active Application Discontinuation
- 2004-03-31 HR HR20040308A patent/HRP20040308A2/xx not_active Application Discontinuation
- 2004-04-21 ZA ZA200403035A patent/ZA200403035B/en unknown
- 2004-04-22 EC EC2004005076A patent/ECSP045076A/es unknown
- 2004-04-23 MA MA27653A patent/MA27684A1/fr unknown
-
2005
- 2005-05-20 US US11/133,751 patent/US20050256167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL160524A0 (en) | 2004-07-25 |
EP1432691A1 (en) | 2004-06-30 |
BR0212986A (pt) | 2004-08-17 |
US20040063691A1 (en) | 2004-04-01 |
CA2459745A1 (en) | 2003-05-15 |
WO2003040107A8 (en) | 2004-07-29 |
CN1599724A (zh) | 2005-03-23 |
US20050256167A1 (en) | 2005-11-17 |
RU2004112770A (ru) | 2005-10-10 |
UY27450A1 (es) | 2003-04-30 |
KR20040040472A (ko) | 2004-05-12 |
CO5560560A2 (es) | 2005-09-30 |
NZ531841A (en) | 2005-09-30 |
NO20041216L (no) | 2004-05-05 |
AR036608A1 (es) | 2004-09-22 |
PE20030547A1 (es) | 2003-08-18 |
WO2003040107A1 (en) | 2003-05-15 |
PL369326A1 (en) | 2005-04-18 |
JP2005508384A (ja) | 2005-03-31 |
US6960601B2 (en) | 2005-11-01 |
HRP20040308A2 (en) | 2006-08-31 |
MXPA04002037A (es) | 2004-06-07 |
MA27684A1 (fr) | 2006-01-02 |
CN1865248A (zh) | 2006-11-22 |
HN2002000266A (es) | 2003-11-16 |
ZA200403035B (en) | 2005-04-21 |
ECSP045076A (es) | 2004-05-28 |
GT200200188A (es) | 2003-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
NO20051600L (no) | 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer | |
DK1533292T3 (da) | Dibenzylaminforbindelse og medicinsk anvendelse deraf | |
HUP0303891A2 (hu) | Gyógyhatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
NO20054224L (no) | Nye 2-pyridinkarboksamidderivater | |
DE60336850D1 (en) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
NO20050828L (no) | lndol-3-svovelderivater | |
NO20070606L (no) | Inhibitorer av IAP | |
PA8509301A1 (es) | Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias | |
HUP0101204A2 (hu) | HIV-gátló pirimidinszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
PL401636A1 (pl) | Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna | |
MXPA05007496A (es) | Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes. | |
NO20055568L (no) | Substituerte 1,4-diazepiner og anvendelser derav | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
NO20060847L (no) | Substituert 2-aminotetralin til behandling av depresjon | |
ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
ATE482933T1 (de) | Sulfopyrrolderivate | |
DE60316436D1 (de) | Amidderivate als inhibitoren der enzymatischen aktivität von renin | |
MXPA05006889A (es) | Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. | |
MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
EA200301171A1 (ru) | Новые соединения трициклических дигидрохинолинов, способ их получения и фармацевтические композиции, содержащие их |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |